Aggravation of psoriasis by Aggravation of psoriasis by antimalarials: A comment on the antimalarials: A comment on the pathogenic mechanism pathogenic mechanism Sir, Exacerbation of psoriasis in patients taking antimalarials is mentioned in all dermatology textbooks, but the underlying mechanism has not been explained in full. It is estimated that up to 18% of patients with psoriasis would develop an exacerbation of their disease following antimalarial therapy. In contrast to lithium and beta blockers, antimalarials do not induce psoriasis de novo, but they only trigger already existing psoriasis, via a pharmacologic mechanism, probably due to an alteration of the activity of enzymes involved in the epidermal proliferation process. Wolf et al. [1] have shown that hydroxychloroquine inhibited transglutaminase activity in a concentration-dependent manner. This is suggested to cause an initial break in the barrier function of the epidermis, followed by a physiologic response of the epidermis aimed at barrier restoration. This rather nonspecific stimulus to epidermal proliferation is suggested to be sufficient to trigger psoriasis in predisposed individuals. That antimalarial drugs only trigger latent psoriasis and do not induce psoriasis de novo can be suspected from the fact that psoriasis cleared Letters to Editor up completely after withdrawal of the drug in only 30% of patients on antimalarials, as compared with more than 60% of those receiving lithium and nearly 50% of those receiving beta blockers. This is probably also why the incubation period of the cases induced by antimalarial drugs is much shorter than that of the cases induced by lithium and beta blockers. Possibly, in triggered psoriasis (as in antimalarials), the drug only sets off with a chain of pathologic events previously programmed and ready to be set off; whereas in true drug-induced cases (as in some cases induced by lithium and beta blockers), the drug is supposed to cause more profound changes and therefore more time is needed for these changes to occur. [1, 2] Herein, I would like to suggest that antimalarials' induction of psoriasis could be partly attributed to their inhibition of cholesterol biosynthesis as well.
Cholesterol biosynthesis by keratinocytes is documented to be fundamental to the integrity of epidermal barrier function. It is shown that topical application of lovastatin to the skin of hairless mice led to the development of epidermal hyperplasia, erythema, scaling, and increased DNA synthesis. This effect, being secondary to the disruption of skin barrier as the result of decreased production of cholesterol by keratinocytes, was aborted with concomitant application of cholesterol. [3] An important point needing attention is that though topically induced statins induce epidermal barrier dysfunction, the risk of exacerbation of psoriasis with orally administered statins is extremely low. In fact, it has been shown that pharmacologic doses of lovastatin do not worsen the course of psoriasis; and though gemfibrozil, an anti-triglyceride agent, has been reported to exacerbate psoriasis, statins have not been reported to do so; and even the lovastatin manufacturer (Merck Sharp and Dome, Rahway, NJ, USA) has anecdotal evidence that the condition of some psoriatic subjects improves when this drug is administered. It is most likely that the beneficial immunomodulatory effects of statins on immunocytes outweigh their untoward effect on surface lipids or they have not enough bioavailability to keratinocytes to affect keratinocytic cholesterol synthesis. [4] There are several reports of aggravation of psoriasis with terbinafine, which is explained by the ability of this agent to inhibit squalene epoxidase, a pivotal enzyme in mammalian cholesterol biosynthesis. [5] Interestingly, both chloroquine and hydroxychloroquine are reported to significantly decrease serum cholesterol levels, hence neutralizing the dyslipidemia seen in systemic lupus erythematosus patients taking steroids. [6, 7] Chloroquine is shown to be a potent inhibitor of cholesterol biosynthesis by isolated rat hepatocytes. It does not affect fatty acid synthesis by isolated hepatocytes, suggesting that it acts on the cholesterol biosynthetic pathway beyond the cytosolic acetyl-coA branch-point of cholesterol and fatty acid synthesis. [8] Therefore, it could be deduced that antimalarials' inhibition of cholesterol biosynthesis contributes to the epidermal barrier dysfunction induced by their transglutaminase inhibition, which can exacerbate psoriasis in genetically predisposed individuals by triggering epidermal hyperproliferation. This dual mechanism explains the relatively high incidence of aggravation of psoriasis by these agents, which has attracted the attention of all authors of dermatology textbooks.
Predicted B-cell epitopes on 18 Predicted B-cell epitopes on 18 kDa antigen of kDa antigen of Haemophilus Haemophilus ducreyi ducreyi Sir, Chancroid is an important sexually transmitted infection. This infection is caused by Haemophilus ducreyi.
[1] This fastidious, gram-negative coccobacilli dies rapidly outside the human host, making diagnostic testing using culture methods difficult.
[1]
Haemophilus ducreyi infection is predominantly seen in tropical resource-poor regions of the world, where it is frequently the most common etiological cause of genital ulceration.
[2] One major goal of current chancroid research is to identify antigens which are immunogenic and could form the basis of a vaccine against Haemophilus ducreyi infection.
[2] Based on the advance in bioinformatics, the immunomics becomes a new alternative in vaccine development. [3] [4] Advanced technologies for vaccine development, such as genome sequence analysis, microarrays, proteomics approach and high-throughput cloning, bioinformatics database tools and computational vaccinology, can be applied for vaccine development for several diseases, including emerging diseases. Faced with the expanding volume of information now available from genome databases, vaccinologists are turning to epitope mapping tools to screen vaccine candidates. [3] [4] New databases have been launched in order to facilitate epitope prediction. [3] [4] Immunity to Haemophilus ducreyi involves B lymphocytes that provide Haemophilus ducreyi-specific antibodies. Spinola et al. found that Haemophilus ducreyi expressed an 18,000-molecular weight outer membrane protein (18 kDa) that contained a conserved surface-exposed epitope recognized by monoclonal antibody 3B9, and monoclonal antibody 3B9 cross-reacted with proteins of similar molecular weight found in many Haemophilus sp. strains, including P6, a candidate vaccine for Haemophilus influenzae. [5] [6] Finding specific epitope from this region can be expected. The main aim of this study is to find potential B-cell-specific epitopes of Haemophilus ducreyi. Here, the author reports the data from the computational analysis of Haemophilus ducreyi to find potential B-cell epitopes using a new immunomics technology.
The author performed computation analysis of available Haemophilus ducreyi 18 kDa sequence to find potential B-cell
